The DOI matches its OpenAlex record; 4 of the 4 references it cites were found in a registry or an index.
A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group
Abstract
OBJECTIVE: To evaluate the efficacy and safety of high-dose tacrine hydrochloride over 30 weeks in patients with probable Alzheimer's disease. DESIGN: A 30-week randomized, double-blind, placebo-controlled, parallel-group trial. SETTING: Outpatients at 33 US centers. PATIENTS: Men and women at least 50 years of age with mild to moderate Alzheimer's disease and otherwise in good health. INTERVENTIONS: Group 1 received placebo; group 2 received 40 mg/d of tacrine for 6 weeks, then 80 mg/d for 24 weeks; groups 3 and 4 received 40 mg/d of tacrine for 6 weeks, 80 mg/d for 6 weeks, and 120 mg/d for 6 weeks. Group 3 remained on a dosage of 120 mg/d for a total of 18 weeks; after 6 weeks at 120 mg/d, group 4 titrated to 160 mg/d for the last 12 weeks. PRIMARY OUTCOME MEASURES: Clinician Interview-Based Impression (CIBI), Alzheimer's Disease Assessment Scale--Cognitive subscale (ADAS-Cog), and Final Comprehensive Consensus Assessment (FCCA). RESULTS: A total of 663 patients entered the study; 653 patients were included in an intent-to-treat (ITT) analysis; 263 had evaluable data at 30 weeks. The results of the ITT analysis revealed significant (P < or = .05) dose-response trends and between-group comparisons on CIBI and ADAS-Cog. In evaluable patients, significant dose-response trends were observed for all three primary measures (P < or = .001). Significant differences in favor of 160 mg/d of tacrine vs placebo were observed on the CIBI (P < or = .002) and ADAS-Cog and FCCA (P < or = .001), as well as caregiver-global and quality-of-life assessments (P < or = .05). On the CIBI, 23% and 42% of tacrine-treated patients in the ITT and evaluable-patient populations, respectively, were rated improved compared with 17% and 18% of placebo patients, respectively. The primary reasons for withdrawal of tacrine-treated patients were asymptomatic liver transaminase elevations (28%) and gastrointestinal complaints (16%). These adverse events were reversible on discontinuation of treatment, and many patients were able to restart tacrine. CONCLUSIONS: Tacrine produced statistically significant, dose-related improvements on objective performance-based tests, clinician- and caregiver-rated global evaluations, and measures of quality of life. There was no evidence that the large number of patient withdrawals biased the overall conclusions of the study.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
SELECTIVE LOSS OF CENTRAL CHOLINERGIC NEURONS IN ALZHEIMER'S DISEASE
DAVIES, P. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91936-x · Cited by 3,565
Alzheimer disease: Evidence for selective loss of cholinergic neurons in the nucleus basalis
Whitehouse, P. J., Price, D. L., Clark, A. W., Coyle, J. T., & DeLong, M. R. (1981) · Annals of Neurology · doi:10.1002/ana.410100203 · Cited by 1,736
A Double-Blind, Placebo-Controlled Multicenter Study of Tacrine for Alzheimer's Disease
Davis, K. L., Thal, L. J., Gamzu, E. R., Davis, C. S., Woolson, R. F., Gracon, S. I., Drachman, D. A., Schneider, L. S., Whitehouse, P. J., Hoover, T. M., et al. (1992) · New England Journal of Medicine · doi:10.1056/nejm199210293271801 · Cited by 626
Cited by
A Controlled Trial of Selegiline, Alpha-Tocopherol, or Both as Treatment for Alzheimer's Disease
Sano, M., Ernesto, C., Thomas, R. G., Klauber, M. R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C. W., Pfeiffer, E., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704243361704 · Cited by 2,380
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Doody, R. S., Stevens, J. C., Beck, C., Dubinsky, R. M., Kaye, J. A., Gwyther, L., Mohs, R. C., Thal, L. J., Whitehouse, P. J., DeKosky, S. T., et al. (2001) · Neurology · doi:10.1212/wnl.56.9.1154 · Cited by 1,720
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
Rogers, S. L., Farlow, M. R., Doody, R. S., Mohs, R., Friedhoff, L. T., & Donepezil Study Group* (1998) · Neurology · doi:10.1212/wnl.50.1.136 · Cited by 1,618
A Placebo-Controlled, Double-blind, Randomized Trial of an Extract of Ginkgo Biloba for Dementia
Le Bars, P. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03550160047037 · Cited by 966
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Spector, A., Thorgrimsen, L., Woods, B., Royan, L., Davies, S., Butterworth, M., & Orrell, M. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.183.3.248 · Cited by 876
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
Hepatotoxic Effects of Tacrine Administration in Patients With Alzheimer's Disease
Watkins, P. B. (1994) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1994.03510370044030 · Cited by 829
Rogers, S. L. (1998) · Archives of Internal Medicine · doi:10.1001/archinte.158.9.1021 · Cited by 773
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad, B., Engedal, K., Soininen, H., Verhey, F., Waldemar, G., Wimo, A., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 727
A review on cholinesterase inhibitors for Alzheimer’s disease
Anand, P., & Singh, B. (2013) · Archives of Pharmacal Research · doi:10.1007/s12272-013-0036-3 · Cited by 709
Bodick, N. C., Offen, W. W., Levey, A. I., Cutler, N. R., Gauthier, S. G., Satlin, A., Shannon, H. E., Tollefson, G. D., Rasmussen, K., Bymaster, F. P., et al. (1997) · Archives of Neurology · doi:10.1001/archneur.1997.00550160091022 · Cited by 692
Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease
Korth, C., May, B. C. H., Cohen, F. E., & Prusiner, S. B. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.161274798 · Cited by 673
Auld, D. S., Kornecook, T. J., Bastianetto, S., & Quirion, R. (2002) · Progress in Neurobiology · doi:10.1016/s0301-0082(02)00079-5 · Cited by 666
Statistical Considerations in the Intent-to-Treat Principle
Lachin, J. M. (2000) · Controlled Clinical Trials · doi:10.1016/s0197-2456(00)00046-5 · Cited by 652
“The clinical trial of tacrine in Alzheimer’s disease [31] illustrates the advantages of this strategy.”
BackgroundSchneider, L. S., Mangialasche, F., Andreasen, N., Feldman, H., Giacobini, E., Jones, R., Mantua, V., Mecocci, P., Pani, L., Winblad, B., et al. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12191 · Cited by 651
Smith, S., Lamping, D., Banerjee, S., Harwood, R., Foley, B., Smith, P., Cook, J., Murray, J., Prince, M., Levin, E., et al. (2005) · Health Technology Assessment · doi:10.3310/hta9100 · Cited by 639
Self-citationWilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 626
Poirier, J., Delisle, M. C., Quirion, R., Aubert, I., Farlow, M., Lahiri, D., Hui, S., Bertrand, P., Nalbantoglu, J., & Gilfix, B. M. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.26.12260 · Cited by 595
Acute stress facilitates long-lasting changes in cholinergic gene expression
Kaufer, D., Friedman, A., Seidman, S., & Soreq, H. (1998) · Nature · doi:10.1038/30741 · Cited by 588
Heinrich, M., & Lee Teoh, H. (2004) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2004.02.012 · Cited by 584
Clinical Course of Hypertrophic Cardiomyopathy in a Regional United States Cohort
Maron, B. J. (1999) · JAMA · doi:10.1001/jama.281.7.650 · Cited by 554
Estrogen for Alzheimer’s disease in women: Randomized, double-blind, placebo-controlled trial
Henderson, V. W., Paganini-Hill, A., Miller, B. L., Elble, R. J., Reyes, P. F., Shoupe, D., McCleary, C. A., Klein, R. A., Hake, A. M., & Farlow, M. R. (2000) · Neurology · doi:10.1212/wnl.54.2.295 · Cited by 550
Estrogen Replacement Therapy and Risk of Alzheimer Disease
Paganini‐Hill, A. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.19.2213 · Cited by 524
Maurice, T., Lockhart, B. P., & Privat, A. (1996) · Brain Research · doi:10.1016/0006-8993(95)01032-7 · Cited by 521
Alzheimer's disease: Etiologies, pathophysiology, cognitive reserve, and treatment opportunities
Cummings, J. L., Vinters, H. V., Cole, G. M., & Khachaturian, Z. S. (1998) · Neurology · doi:10.1212/wnl.51.1_suppl_1.s2 · Cited by 519
Castellani, R. J., Rolston, R. K., & Smith, M. A. (2010) · Disease-a-Month · doi:10.1016/j.disamonth.2010.06.001 · Cited by 519
Therapeutic applications of compounds in the Magnolia family
Lee, Y.-J., Lee, Y. M., Lee, C.-K., Jung, J. K., Han, S. B., & Hong, J. T. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.01.010 · Cited by 481
Ferreira, A., Proença, C., Serralheiro, M. L. M., & Araújo, M. E. M. (2006) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2006.04.010 · Cited by 480
A Review of 12 Commonly Used Medicinal Herbs
O'Hara, M. (1998) · Archives of Family Medicine · doi:10.1001/archfami.7.6.523 · Cited by 477
Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine1
WANG, R., YAN, H., & TANG, X.-C. (2006) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2006.00255.x · Cited by 470
Suh, Y.-H., & Checler, F. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.3.469 · Cited by 467
National Estimates of the Quantity and Cost of Informal Caregiving for the Elderly with Dementia*
Langa, K. M., Chernew, M. E., Kabeto, M. U., Regula Herzog, A., Beth Ofstedal, M., Willis, R. J., Wallace, R. B., Mucha, L. M., Straus, W. L., & Fendrick, A. M. (2001) · Journal of General Internal Medicine · doi:10.1046/j.1525-1497.2001.10123.x · Cited by 456
Fallin, D., Cohen, A., Essioux, L., Chumakov, I., Blumenfeld, M., Cohen, D., & Schork, N. J. (2001) · Genome Research · doi:10.1101/gr.148401 · Cited by 421
A 7 Minute Neurocognitive Screening Battery Highly Sensitive to Alzheimer's Disease
Solomon, P. R., Hirschoff, A., Kelly, B., Relin, M., Brush, M., DeVeaux, R. D., & Pendlebury, W. W. (1998) · Archives of Neurology · doi:10.1001/archneur.55.3.349 · Cited by 418
Treatment of Alzheimer's Disease
Mayeux, R., & Sano, M. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911253412207 · Cited by 385
Cholinesterase Inhibitors: A New Class of Psychotropic Compounds
Cummings, J. L. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.4 · Cited by 384
Galantamine: A Review of its Use in Alzheimer??s Disease
Scott, L. J., & Goa, K. L. (2000) · Drugs · doi:10.2165/00003495-200060050-00008 · Cited by 383
Nordberg, A., & Svensson, A.-L. (1998) · Drug Safety · doi:10.2165/00002018-199819060-00004 · Cited by 381
Intent-to-Treat Analysis for Longitudinal Studies with Drop-Outs
Little, R., & Yau, L. (1996) · Biometrics · doi:10.2307/2532847 · Cited by 380
Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors
Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365
Wilkinson, D. G., Francis, P. T., Schwam, E., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 365
Fox, N. C., Cousens, S., Scahill, R., Harvey, R. J., & Rossor, M. N. (2000) · Archives of Neurology · doi:10.1001/archneur.57.3.339 · Cited by 360
Structural roles of acetylcholinesterase variants in biology and pathology
Grisaru, D., Sternfeld, M., Eldor, A., Glick, D., & Soreq, H. (1999) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.1999.00693.x · Cited by 355
Qaseem, A., Snow, V., Cross, J. T., Forciea, M. A., Hopkins, R., Shekelle, P., Adelman, A., Mehr, D., Schellhase, K., Campos-Outcalt, D., et al. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00008 · Cited by 354
Practice parameter: Management of dementia (an evidence-based review)
Oken, B. S. (2001) · Neurology · doi:10.1212/wnl.57.12.2323 · Cited by 351
Current Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 345
Coyle, J., & Kershaw, P. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01101-x · Cited by 335
Cholinergic dysfunction in diseases with Lewy bodies
Tiraboschi, P., Hansen, L. A., Alford, M., Sabbagh, M. N., Schoos, B., Masliah, E., Thal, L. J., & Corey-Bloom, J. (2000) · Neurology · doi:10.1212/wnl.54.2.407 · Cited by 328
The use of unequal randomisation ratios in clinical trials: A review
Dumville, J. C., Hahn, S., Miles, J. N. V., & Torgerson, D. J. (2006) · Contemporary Clinical Trials · doi:10.1016/j.cct.2005.08.003 · Cited by 320
Acetylcholinesterase inhibitors in Alzheimer’s disease
McGleenon, Dynan, & Passmore (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00026.x · Cited by 317
Pettegrew, J. W., Levine, J., & McClure, R. J. (2000) · Molecular Psychiatry · doi:10.1038/sj.mp.4000805 · Cited by 304
Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends
Bachurin, S. O., Bovina, E. V., & Ustyugov, A. A. (2017) · Medicinal Research Reviews · doi:10.1002/med.21434 · Cited by 304
Efficacy of donepezil in mild cognitive impairment: A randomized placebo-controlled trial
Salloway, S., Ferris, S., Kluger, A., Goldman, R., Griesing, T., Kumar, D., & Richardson, S. (2004) · Neurology · doi:10.1212/01.wnl.0000134664.80320.92 · Cited by 300
The limbic system: an anatomic, phylogenetic, and clinical perspective
(1997) · The Journal of Neuropsychiatry and Clinical Neurosciences · doi:10.1176/jnp.9.3.315 · Cited by 293
Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
Knopman, D., Schneider, L., Davis, K., Talwalker, S., Smith, F., Hoover, T., & Gracon, S. (1996) · Neurology · doi:10.1212/wnl.47.1.166 · Cited by 293
Acetylcholinesterase inhibitors: novel activities of old molecules
RACCHI, M. (2004) · Pharmacological Research · doi:10.1016/j.phrs.2003.12.027 · Cited by 288
Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease
Morris, J. C., Cyrus, P. A., Orazem, J., Mas, J., Bieber, F., Ruzicka, B. B., & Gulanski, B. (1998) · Neurology · doi:10.1212/wnl.50.5.1222 · Cited by 287
Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial
Rockwood, K. (2001) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.71.5.589 · Cited by 279
The Cholinergic Hypothesis of Neuropsychiatric Symptoms in Alzheimer's Disease
Cummings, J. L., & Back, C. (1998) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-199821001-00009 · Cited by 274
Exploring the Etiology of Alzheimer Disease Using Molecular Genetics
Lendon, C. L. (1997) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1997.03540340059034 · Cited by 273
Cholinesterase Inhibitors for Alzheimer??s Disease
Grutzendler, J., & Morris, J. C. (2001) · Drugs · doi:10.2165/00003495-200161010-00005 · Cited by 270
Ginkgo for Memory Enhancement: A Randomized Controlled Trial
Solomon, P. R., Adams, F., Silver, A., Zimmer, J., & DeVeaux, R. (2002) · JAMA · doi:10.1001/jama.288.7.835 · Cited by 269
Meta‐analysis of continuous outcome data from individual patients
Higgins, J. P. T., Whitehead, A., Turner, R. M., Omar, R. Z., & Thompson, S. G. (2001) · Statistics in Medicine · doi:10.1002/sim.918 · Cited by 265
A simple and valid tool distinguished efficacy from effectiveness studies
Gartlehner, G., Hansen, R. A., Nissman, D., Lohr, K. N., & Carey, T. S. (2006) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2006.01.011 · Cited by 207
Determining the minimum clinically important differences for outcomes in the DOMINO trial
Howard, R., Phillips, P., Johnson, T., O'Brien, J., Sheehan, B., Lindesay, J., Bentham, P., Burns, A., Ballard, C., Holmes, C., et al. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2607 · Cited by 185
Self-citationAlzheimer’s disease and related dementias increase costs of comorbidities in managed Medicare
Hill, J. W., Futterman, R., Duttagupta, S., Mastey, V., Lloyd, J. R., & Fillit, H. (2002) · Neurology · doi:10.1212/wnl.58.1.62 · Cited by 181
Davis, K. L., & Powchick, P. (1995) · The Lancet · doi:10.1016/s0140-6736(95)90526-x · Cited by 177
Confusional State in Stroke: Relation to Preexisting Dementia, Patient Characteristics, and Outcome
Hénon, H., Lebert, F., Durieu, I., Godefroy, O., Lucas, C., Pasquier, F., & Leys, D. (1999) · Stroke · doi:10.1161/01.str.30.4.773 · Cited by 168
The P2X7 Receptor: Central Hub of Brain Diseases
Andrejew, R., Oliveira-Giacomelli, Á., Ribeiro, D. E., Glaser, T., Arnaud-Sampaio, V. F., Lameu, C., & Ulrich, H. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00124 · Cited by 162
“…drugs currently available to treat AD have only palliative effects and consist of acetylcholinesterase inhibition to optimize cholinergic activity (Knapp et al., 1994; Rogers and Friedhoff, 1996; Trinh et al., 2003), and the NMDA receptor antagonist memantine (Cosman et al., 2007; Lipton, 2007;…”
BackgroundDifferences between clinical trials and postmarketing use
Martin, K., Bégaud, B., Latry, P., Miremont‐Salamé, G., Fourrier, A., & Moore, N. (2004) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.2003.01953.x · Cited by 157
Combined glutathione-S -transferase M1 and T1 genetic polymorphism and tacrine hepatotoxicity
Simon, T. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104944 · Cited by 122
Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease
Doody, R. S., Dunn, J. K., Clark, C. M., Farlow, M., Foster, N. L., Liao, T., Gonzales, N., Lai, E., & Massman, P. (2001) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051272 · Cited by 118
AMPA potentiator treatment of cognitive deficits in Alzheimer disease
Chappell, A. S., Gonzales, C., Williams, J., Witte, M. M., Mohs, R. C., & Sperling, R. (2007) · Neurology · doi:10.1212/01.wnl.0000260240.46070.7c · Cited by 89
Kamal, Z., Ullah, F., Ayaz, M., Sadiq, A., Ahmad, S., Zeb, A., Hussain, A., & Imran, M. (2015) · Biological Research · doi:10.1186/s40659-015-0011-1 · Cited by 86
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84
The Relationship Between Donepezil and Behavioral Disturbances in Patients With Alzheimer's Disease
Cummings, J. L., Donohue, J. A., & Brooks, R. L. (2000) · The American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200005000-00008 · Cited by 71
The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
Cappell, J., Herrmann, N., Cornish, S., & Lanctôt, K. L. (2010) · CNS Drugs · doi:10.2165/11539530-000000000-00000 · Cited by 57
Guidelines for the treatment of Alzheimer’s disease from the Italian Association of Psychogeriatrics
Caltagirone, C., Bianchetti, A., Luca, M. D., Mecocci, P., Padovani, A., Pirfo, E., Scapicchio, P., Senin, U., Trabucchi, M., & Musicco, M. (2005) · Drugs & Aging · doi:10.2165/00002512-200522001-00002 · Cited by 55
Wallin, Å., Minthon, & Wattmo, C. (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s24196 · Cited by 50
Wallin, Å. K., Gustafson, L., Sjögren, M., Wattmo, C., & Minthon, L. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000079201 · Cited by 45
Outcome of Alzheimer's disease: potential impact of cholinesterase inhibitors
Gillette-Guyonnet, S., Andrieu, S., Cortes, F., Nourhashemi, F., Cantet, C., Ousset, P.-J., Reynish, E., Grandjean, H., & Vellas, B. (2006) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/61.5.516 · Cited by 41
Trinh, N.-H., Hoblyn, J., Mohanty, S., & Yaffe, K. (2003) · JAMA · doi:10.1001/jama.289.2.210 · Cited by 37
In-vitro stability and metabolism of a tacrine–silibinin codrug
Zenger, K., Chen, X., Decker, M., & Kraus, B. (2013) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12070 · Cited by 13
(2000) · doi:10.1002/1531-8249(200012)48:6
Metadata
- Authors
- Knapp, M. J.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1994-04-06
- Volume
- 271
- Issue
- 13
- Pages
- 985
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W4233035841
- Cited by
- 1,004
- References
- 4
- FWCI
- 77.80
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.